A Phase 4 interventional study of Acyclovir 50 MG/ML and Placebo in Herpes Simplex 2 and Meningitis, Viral, sponsored by Jacob Bodilsen. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Jacob Bodilsen · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine whether active treatment with (val)acyclovir is superior for treatment of viral meningitis compared with placebo assessed by numbers meeting a primary, objective endpoint at 7 days after randomisation
268 studies on the registry are indexed under Meningitis; 28 are open to participants now.
This study's planned enrollment of 150 is below the median of 260 across 185 interventional studies indexed under Meningitis.
Browse Meningitis studies →Jacob Bodilsen is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults ≥18 years of age admitted on suspicion of viral meningitis defined as:
Exclusion Criteria:
Patients fulfilling any of the following criteria will be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Randomisation to 7 days of active treatment with IV aciclovir 10 mg/kg q8h and possibility for oral step-down therapy with valaciclovir 1g q8h, or placebo (IV q8h and/or oral q8h).
Drug: Acyclovir 50 MG/ML
Randomisation to 7 days of IV and/or oral placebo.
Drug: Placebo
Drug page: AcyclovirStudies of AcyclovirAcyclovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients are randomised to active treatment with IV acyclovir with the possibility of step-down to valacyclovir. If the treating physician prefers, initial IV treatment can be omitted and the patient can be treated with valacyclovir throughout the study period.
Also known as: Valacyclovir
Placebo either in IV formulation or as tablets identical to valacyclovir tablets.
Primary endpoint (proportion with a Total Morbidity Score)
The proportion with a Total Morbidity Score (TMS) \>6 is considered treatment failure. The score is a sum of scores for headache (range 0 to 6), nuchal rigidity (range 0 to 4), photophobia (range 0 to 4), myalgia (range 0 to 4), fever (range 0 to 4), nausea (range 0 to 4). The score thus ranges from 0 to 21 with higher scores indicating more severe symptoms.
Time frame: 7 days since randomisation
Secondary endpoint 1 (Proportion of patients with ≤50% reduction of Total Morbidity Score)
Proportion of patients with ≤50% reduction of Total Morbidity Score since randomisation. Please see characterization of score under primary endpoint.
Time frame: 7 days since randomisation
Secondary endpoint 2 Extended Glasgow outcome scale score
Extended Glasgow outcome scale score. Range 1 to 8 with higher scores indicating better outcome.
Time frame: 7 days, 3 months, and 12 months since randomisation
Secondary endpoint 3 All-cause mortality
All-cause mortality
Time frame: 7 days, 3 months, and 12 months since randomisation
Secondary endpoint 4 EQ-5D-5L
EQ-5D-5L. Comprises 5 questions with an ordinal scale from 1 to 5 with higher scores indicating more morbidity. Finally, a visual analog score is filled ranging from 0 to 100 with higher scores indicating better health.
Time frame: 7 days, 3 months, and 12 months since randomisation
Secondary endpoint 5 Mental Fatigue Scale
Mental Fatigue Scale. Comprises 14 questions with scores from 0 to 3 with higher values suggesting more morbidity. A combined score \>10.5 usually suggests mental fatigue problems.
Time frame: 7 days, 3 months, and 12 months since randomisation
Secondary endpoint 6 (SF-36)
Short Form Health Survey 36 (SF-36). Scores eight different domains from 0 to 100 with higher values indicating no disability.
Time frame: 7 days, 3 months, and 12 months since randomisation
Secondary outcome 7 neurological deficit
Any new neurological deficit reported by patient or observed during clinical examination
Time frame: 7 days, 3 months, and 12 months since randomisation
Secondary outcome 8 Completion of assigned treatment
Completion of assigned treatment (active or placebo) assessed by administered intravenous or oral treatment as signed off by nurses in hospitalized patients and pill counts for patients discharged with oral study drug.
Time frame: 7 days since randomisation
Secondary outcome 9 complications
Peripheral venous line associated complications (i.e. catheter-associated infection, thrombosis, or haemorrhage).
Time frame: 7 days since randomisation
Secondary outcome 10Severe adverse events
Severe adverse events, i.e. incident treatment-emergent serious adverse events.
Time frame: 7 days since randomisation
No study locations are listed for this record.
Plan to share: Yes — Data will be deposited at Mendeley Data (https://data.mendeley.com/).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning six months and ending three years after publication, an anonymized dataset can be shared.
Access criteria: Qualified researchers who provide a methodologically sound proposal.
Data sharing details ↗ · data.mendeley.com
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2031, 59 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Jun 2026 → Jan 2027, primary completion Jun 2028 → Dec 2031 and completion Jun 2029 → Dec 2032.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Acyclovir
Jacob Bodilsen